Literature DB >> 369855

Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids.

I H Patel, R H Levy.   

Abstract

The interaction between valproic acid (VPA) and human serum albumin (HSA) was investigated using the equilibrium dialysis technique under various conditions. Solutions of VPA in HSA (2 x 10(-4) M) were dialyzed against isotonic phosphate buffer at 37 degrees C. Protein and buffer compartments were assayed for VPA by GLC. The free fraction (alpha) of VPA increased from 0.13 at 27 microgram/ml to 0.49 at 103 microgram/ml. Scatchard plots were linear, indicating the existence of one type of binding site. The mean (+/- % SD) number of binding sites per macromolecule was 2.06 +/- 3.7% and the mean (+/- % SD) association constant was 2.69 x 10(4) +/- 15.0% liters/mole. The effects of three anticonvulsants (phenytoin, phenobarbital, and carbamazepine) and four major free fatty acids (FFA) (stearic, palmitic, oleic, and linoleic) on alpha were studied. The free fraction, 0.18, was not affected by phenobarbital (20 and 40 microgram/ml), carbamazepine (10 and 20 microgram/ml) or phenytoin (20 and 40 microgram/ml). Each of the four FFA caused a significant increase in alpha: 19--48% increase at 100 microgram/ml of FFA and 88--118% at 200 microgram/ml.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 369855     DOI: 10.1111/j.1528-1157.1979.tb04779.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  19 in total

Review 1.  Influence of exercise on the pharmacokinetics of drugs.

Authors:  M A van Baak
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

2.  Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.

Authors:  R L Semmes; D D Shen
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

3.  Allosteric properties of the oxyphenbutazone--human serum albumin complex.

Authors:  J H Dröge; L H Janssen; J Wilting
Journal:  Pharm Weekbl Sci       Date:  1983-10-21

4.  Free sodium valproate monitoring.

Authors:  E J Roman; P Ponniah; J B Lambert; N Buchanan
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of valproic acid.

Authors:  R Gugler; G E von Unruh
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

6.  Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 7.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 8.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 9.  Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.

Authors:  James W McAuley; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Intra-dose variation in plasma protein binding of sodium valproate in epileptic patients.

Authors:  J J Marty; C J Kilpatrick; R F Moulds
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.